PhRMA is prepared to accept a cap on drug price increases, biopharma executives involved in drafting the trade association’s response to the Trump administration’s drug pricing blueprint told BioCentury.
The PhRMA board is considering a
Read the full 356 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD